Skip to main
  1. Stocks
  2. Foghorn Therapeutics
  3. Forecast
FHTX

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics (FHTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 0%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Foghorn Therapeutics is constructive because its selective EP300 degrader program appears to offer a better therapeutic window than dual CBP/EP300 inhibition, with preclinical models showing complete responses, tumor regression, and improved platelet preservation versus inobrodib. The company’s pivot toward wholly owned assets after discontinuing FHD-909, combined with a ~40% workforce reduction and roughly $168M of cash at Q2:26, is expected to extend cash runway into H2:29 and support development through an IND targeted for late 2027. That runway gives management time to advance a focused pipeline in multiple myeloma, DLBCL, and T cell lymphomas, while external validation from CellCentric’s 67% ORR in heavily pretreated myeloma underscores the commercial and clinical relevance of the EP300/CBP biology.

Bears say

Foghorn Therapeutics is facing a weakened investment case because FHD-909, its only clinical-stage asset, showed favorable safety and exposure but failed to deliver the efficacy needed to justify further development, implying that SMARCA2/4 synthetic lethality is not translating into a viable therapeutic strategy. The decision by Foghorn and Lilly to wind down the collaboration also removes a meaningful partnered value driver, while the company’s remaining pipeline is now entirely preclinical, with the oral I&I and EP300 assets not expected to be IND-ready until late ’27 and requiring additional capital or a partner. Although the approximately 40% workforce reduction extends runway into H2:29, the lack of clinical validation, delays in the CBP program, and heavier dependence on early-stage assets support a cautious, negative outlook.

Foghorn Therapeutics (FHTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 0% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction

Get the latest Foghorn Therapeutics (FHTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Foghorn Therapeutics (FHTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Foghorn Therapeutics (FHTX) Forecast

Analysts have given Foghorn Therapeutics (FHTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Foghorn Therapeutics (FHTX) has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Foghorn Therapeutics (FHTX)


Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction

Get the latest Foghorn Therapeutics (FHTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Foghorn Therapeutics (FHTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover FHTX stock data and trends